0000000000993879

AUTHOR

Florence Binlich

showing 1 related works from this author

A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.

2014

7022^ Background: Myelofibrosis (MF) is a myeloproliferative neoplasm characterized by dysregulation of the Janus kinase (JAK) pathway resulting in bone marrow fibrosis, splenomegaly, and debilitat...

Cancer ResearchRuxolitinibPathologymedicine.medical_specialtybusiness.industryBone marrow fibrosismedicine.diseasechemistry.chemical_compoundDose findingOncologychemistryPanobinostatCancer researchMedicineIn patientbusinessJanus kinaseMyelofibrosisMyeloproliferative neoplasmmedicine.drugJournal of Clinical Oncology
researchProduct